Tigecycline: Difference between revisions

Revision as of 04:04, 9 January 2014

Tigecycline
TYGACIL^® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

For patient information, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tigecycline (INN) (IPA: Template:IPA) is anglycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence ofantibiotic resistance in bacteria such as Staphylococcus aureus.

US Brand Names

TYGACIL^®

FDA Package Insert

Mechanism of Action

References

@@ Line 1: / Line 1: @@
-{{drugbox |
+__NOTOC__
-| IUPAC_name = ''N''-[(5a''R'',6a''S'',7''S'',9''Z'',10a''S'')-9-(amino-hydroxy-methylidene)-<br />4,7-''bis''(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-<br />5a,6,6a,7-tetrahydro-5''H''-tetracen-2-yl]-2-(''tert''-butylamino)acetamide
+{{Tigecycline}}
-| image = Tigecycline structure.svg
+'''''For patient information, click <u>[[Tigecycline (patient information)|here]]</u>'''''.
-| CAS_number = 220620-09-7
-| ATC_prefix = J01
-| ATC_suffix = AA12
-| PubChem = 5282044
-| DrugBank = APRD01307
-| C=19 | H=39 | N=5 | O=8
-| molecular_weight = 585.65 g/mol
-| bioavailability = NA
-| metabolism = not metabolised
-| elimination_half-life = 42.4 hours
-| protein_bound = 71-89%
-| excretion = 59% biliary, 33% [[Kidney|renal]]
-| pregnancy_AU = D
-| pregnancy_US = D
-| legal_AU = S4
-| legal_US = Rx-only
-| routes_of_administration = IV only
-}}
-{{SI}}
+{{CMG}}
-'''Tigecycline''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[ ˌtaɪgəˈsaɪklin ]}}) is an [[glycylcycline]] [[antibiotic]] developed and marketed by [[Wyeth]] under the brand name '''Tygacil'''. It was given a U.S. [[Food and Drug Administration]] (FDA) fast-track approval and was approved on [[June 17]], [[2005]]. It was developed in response to the growing prevalence of [[antibiotic resistance]] in bacteria such as ''[[Staphylococcus aureus]]''.
+==Overview==
+'''Tigecycline''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[ ˌtaɪgəˈsaɪklin ]}}) is an[[glycylcycline]] [[antibiotic]] developed and marketed by [[Wyeth]] under the brand name '''Tygacil'''. It was given a U.S. [[Food and Drug Administration]] (FDA) fast-track approval and was approved on [[June 17]], [[2005]]. It was developed in response to the growing prevalence of[[antibiotic resistance]] in bacteria such as ''[[Staphylococcus aureus]]''.
-==Pharmacology==
+==Category==
-This antibiotic is the first clinically-available drug in a new class of antibiotics called the [[glycylcyclines]].  It is structurally similar to the [[tetracycline]]s in that it contains a central four-ring carbocyclic skeleton and is actually a derivative of [[minocycline]].  Tigecycline has a substitution at the D-9 position which is believed to confer broad spectrum activity.  The drug inhibits the bacterial 30S [[ribosome]] and is [[bacteriostatic]].
+Glycopeptide
+==US Brand Names==
+TYGACIL<sup>®</sup>
+==FDA Package Insert==
-==Indications==
+'''  [[Tigecycline description|Description]]'''
-Tigecycline is active against many [[Gram-positive]] bacteria, [[Gram-negative]] bacteria and anaerobes – including activity against [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA). It has no activity against ''[[Pseudomonas]]'' spp. or ''[[Proteus (bacterium)|Proteus]]'' spp.  The drug is licenced for the treatment of skin and soft tissue infections as well as intra-abdominal infections.
+'''| [[Tigecycline clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Tigecycline microbiology|Microbiology]]'''
+'''| [[Tigecycline indications and usage|Indications and Usage]]'''
+'''| [[Tigecycline contraindications|Contraindications]]'''
+'''| [[Tigecycline warnings and precautions|Warnings and Precautions]]'''
+'''| [[Tigecycline adverse reactions|Adverse Reactions]]'''
+'''| [[Tigecycline drug interactions|Drug Interactions]]'''
+'''| [[Tigecycline overdosage|Overdosage]]'''
+'''| [[Tigecycline clinical studies|Clinical Studies]]'''
+'''| [[Tigecycline dosage and administration|Dosage and Administration]]'''
+'''| [[Tigecycline how supplied|How Supplied]]'''
+'''| [[Tigecycline labels and packages|Labels and Packages]]'''
-==Dosing==
+==Mechanism of Action==
-Tigecycline is given by slow intravenous infusion (30 to 60 minutes).  A single dose of 100 [[Wiktionary:milligram|mg]] is given first, followed by 50 mg every twelve hours after that.  Patients with impaired liver function need to be given a lower dose.  No adjustment is needed for patients with impaired kidney function.  It is not licensed for use in children.  There is no oral form available.
-==Side Effects==
-The most common side effects of tigecycline are diarrhea, nausea and vomiting. Nausea and vomiting is mild or moderate and usually occurs during the first two days of therapy. Other side effects include pain at the injection site, swelling and irritation; increased or decreased heart rate and infections. As tigecycline is similar to the tetracycline antibiotics,they have similar side effects such as increased sensitivity to sunlight. Also avoid use in children and pregnancy, due to its affects on teeth and bone. As with other antibiotics, overgrowth of organisms that are not susceptible to tigecycline can occur.
 ==References==
-* {{cite journal | author = Rose W, Rybak M | title = Tigecycline: first of a new class of antimicrobial agents. | journal = Pharmacotherapy | volume = 26 | issue = 8 | pages = 1099-110 | year = 2006 | id = PMID 16863487}}
+{{Reflist|2}}
-* {{cite journal | author = Kasbekar N | title = Tigecycline: a new glycylcycline antimicrobial agent. | journal = Am J Health Syst Pharm | volume = 63 | issue = 13 | pages = 1235-43 | year = 2006 | id = PMID 16790575}}
-== External links ==
-* [http://www.tygacil.com/ Tygacil ® ( tigecycline iv ): Antibiotic for Skin Infections]
-{{TetracyclineAntiBiotics}}
-[[Category:Glycylcycline antibiotics]]
-[[de:Tigecyclin]]
+[[Category:Glycopeptide]]
-{{WH}}
+[[Category:Wikinfect]]
-{{WikiDoc Sources}}